NCT04389632 2026-03-16A Study of Sigvotatug Vedotin in Advanced Solid TumorsSeagen Inc.Phase 1 Recruiting1,006 enrolled
NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled